Download PDF
Semin Respir Crit Care Med 2014; 35(03): 391-406
DOI: 10.1055/s-0034-1376401
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medical Therapy of Sarcoidosis

Robert P. Baughman
1   Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
,
Elyse E. Lower
1   Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2014 (online)

    Permissions and Reprints

Abstract

For treatment of sarcoidosis, one should develop a long-term management plan. Factors to be considered include the organ involvement and severity of symptoms. Different organ manifestations may require different treatments. Intensity of treatment is usually based on severity of disease or potential for organ failure or death. Glucocorticoids are quite effective as initial therapy for most forms of sarcoidosis. However, the toxicity associated with long-term treatment often leads to the use of alternative treatments. These include cytotoxic agents such as methotrexate, biologic agents such as the antitumor necrosis factor antibody infliximab, and other anti-inflammatory drugs such as hydroxychloroquine. In some cases, anti-inflammatory drugs may not help. Examples include pulmonary hypertension and fibrosis.

Keywords

sarcoidosis - medical therapy - glucocorticosteroids - immunosuppressive agents - TNF inhibitors
 

  • References

  • 1 Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41 (6) 1424-1438
    CrossrefPubMedGoogle Scholar
  • 2 Swigris JJ, Olson AL, Huie TJ , et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183 (11) 1524-1530
    CrossrefPubMedGoogle Scholar
  • 3 Gerke AK, Yang M, Tang F, Cavanaugh JE, Polgreen PM. Increased hospitalizations among sarcoidosis patients from 1998 to 2008: a population-based cohort study. BMC Pulm Med 2012; 12: 19
    CrossrefPubMedGoogle Scholar
  • 4 Baughman RP, Judson MA, Teirstein A , et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99 (5) 307-315
    CrossrefPubMedGoogle Scholar
  • 5 Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (2) 119-127
    PubMedGoogle Scholar
  • 6 Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15 (1) 52-58
    PubMedGoogle Scholar
  • 7 Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8 (1) 95-103
    CrossrefPubMedGoogle Scholar
  • 8 Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45 (2) 159-169
    CrossrefPubMedGoogle Scholar
  • 9 Barnett CF, Bonura EJ, Nathan SD , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (6) 1455-1461
    CrossrefPubMedGoogle Scholar
  • 10 Baughman RP, Teirstein AS, Judson MA , et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1) 1885-1889
    CrossrefPubMedGoogle Scholar
  • 11 Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis—results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15 (2) 178-182
    PubMedGoogle Scholar
  • 12 Yeager H, Rossman MD, Baughman RP , et al; ACCESS Research Group. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (2) 147-153
    PubMedGoogle Scholar
  • 13 Chambellan A, Turbie P, Nunes H, Brauner M, Battesti JP, Valeyre D. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest 2005; 127 (2) 472-481
    CrossrefPubMedGoogle Scholar
  • 14 Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest 2009; 136 (5) 1371-1380
    CrossrefPubMedGoogle Scholar
  • 15 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (5) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 16 Mehta D, Lubitz SA, Frankel Z , et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133 (6) 1426-1435
    CrossrefPubMedGoogle Scholar
  • 17 Spruit MA, Thomeer MJ, Gosselink R , et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60 (1) 32-38
    CrossrefPubMedGoogle Scholar
  • 18 Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012; 41 (6 Pt 2) e289-e302
    CrossrefPubMedGoogle Scholar
  • 19 Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104 (5) 717-723
    CrossrefPubMedGoogle Scholar
  • 20 McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 21 Baughman RP, Iannuzzi MC, Lower EE , et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (3) 198-204
    PubMedGoogle Scholar
  • 22 Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58 (4) 339-343
    CrossrefPubMedGoogle Scholar
  • 23 Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013; 41 (3) 621-626
    CrossrefPubMedGoogle Scholar
  • 24 Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 2011; 189 (2) 167-172
    CrossrefPubMedGoogle Scholar
  • 25 Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56 (5) 559-570
    CrossrefPubMedGoogle Scholar
  • 26 Kravitz JN, Berry MW, Schabel SI, Judson MA. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest 2013; 143 (5) 1414-1421
    CrossrefPubMedGoogle Scholar
  • 27 Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (2) 108-116
    PubMedGoogle Scholar
  • 28 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (2) 296-302
    CrossrefPubMedGoogle Scholar
  • 29 Baughman RP, Lower EE, Kaufman AH. Ocular sarcoidosis. Semin Respir Crit Care Med 2010; 31 (4) 452-462
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T ; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113 (6) 1020-1027
    CrossrefPubMedGoogle Scholar
  • 31 Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013; 29 (5) 501-507
    CrossrefPubMedGoogle Scholar
  • 32 Galor A, Jabs DA, Leder HA , et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115 (10) 1826-1832
    CrossrefPubMedGoogle Scholar
  • 33 Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (1) 43-48
    PubMedGoogle Scholar
  • 34 Sahoo DH, Bandyopadhyay D, Xu M , et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38 (5) 1145-1150
    CrossrefPubMedGoogle Scholar
  • 35 Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (1) 26-33
    PubMedGoogle Scholar
  • 36 Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106 (1) 111-118
    CrossrefPubMedGoogle Scholar
  • 37 Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250 (5) 713-720
    CrossrefPubMedGoogle Scholar
  • 38 Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005; 43 (1) 7-11
    CrossrefPubMedGoogle Scholar
  • 39 Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008; 68 (10) 1361-1383
    CrossrefPubMedGoogle Scholar
  • 40 Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25 (3) 334-340
    CrossrefPubMedGoogle Scholar
  • 41 Baughman RP, Judson MA, Teirstein A , et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9 (3) 155-161
    CrossrefPubMedGoogle Scholar
  • 42 Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135 (2) 468-476
    CrossrefPubMedGoogle Scholar
  • 43 Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med 2008; 29 (3) 475-492 , ix
    CrossrefPubMedGoogle Scholar
  • 44 Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64 (5) 691-696
    CrossrefPubMedGoogle Scholar
  • 45 Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157 (16) 1864-1868
    CrossrefPubMedGoogle Scholar
  • 46 Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52 (9) 875-879
    CrossrefPubMedGoogle Scholar
  • 47 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155 (8) 846-851
    CrossrefPubMedGoogle Scholar
  • 48 Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102 (7) 449-460
    CrossrefPubMedGoogle Scholar
  • 49 Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105 (1) 101-105
    CrossrefPubMedGoogle Scholar
  • 50 Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72 (4) 337-340
    CrossrefPubMedGoogle Scholar
  • 51 Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103 (2) 268-273
    CrossrefPubMedGoogle Scholar
  • 52 Chapelon-Abric C, de Zuttere D, Duhaut P , et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83 (6) 315-334
    CrossrefPubMedGoogle Scholar
  • 53 Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013; 29 (9) 1034-1041
    CrossrefPubMedGoogle Scholar
  • 54 Hiramitsu S, Morimoto S, Uemura A , et al. National survey on status of steroid therapy for cardiac sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (3) 210-213
    PubMedGoogle Scholar
  • 55 Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT ; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25) 3133-3140
    CrossrefPubMedGoogle Scholar
  • 56 Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol 2007; 26 (11) 2001-2003
    CrossrefPubMedGoogle Scholar
  • 57 Barnabe C, McMeekin J, Howarth A, Martin L. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol 2008; 35 (8) 1686-1687
    PubMedGoogle Scholar
  • 58 Crouser ED, Lozanski G, Fox CC, Hauswirth DW, Raveendran R, Julian MW. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-alpha therapy. Chest 2010; 137 (6) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 59 Schuller JL, Zipse M, Crawford T , et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012; 23 (9) 925-929
    CrossrefPubMedGoogle Scholar
  • 60 Zipse MM, Sauer WH. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med 2013; 19 (5) 485-492
    CrossrefPubMedGoogle Scholar
  • 61 Cremers JP, Drent M, Baughman RP, Wijnen PA, Koek GH. Therapeutic approach of hepatic sarcoidosis. Curr Opin Pulm Med 2012; 18 (5) 472-482
    CrossrefPubMedGoogle Scholar
  • 62 Kennedy PT, Zakaria N, Modawi SB , et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006; 18 (7) 721-726
    CrossrefPubMedGoogle Scholar
  • 63 Cremers J, Drent M, Driessen A , et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012; 24 (1) 17-24
    CrossrefPubMedGoogle Scholar
  • 64 Kahi CJ, Saxena R, Temkit M , et al. Hepatobiliary disease in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (2) 117-123
    PubMedGoogle Scholar
  • 65 Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber Jr FL. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 2003; 163 (5) 615-620
    CrossrefPubMedGoogle Scholar
  • 66 Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12 (7) 479-483
    PubMedGoogle Scholar
  • 67 Adams JS. Hypercalcemia and hypercalcuria. Semin Resp Med 1992; 13: 402-410
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010; 31 (4) 474-484
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Mason RS, Frankel T, Chan YL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med 1984; 100 (1) 59-61
    CrossrefPubMedGoogle Scholar
  • 70 Lavender TW, Martineau AR, Quinton R, Schwab U. Severe hypercalcaemia following vitamin D replacement for tuberculosis-associated hypovitaminosis D. Int J Tuberc Lung Dis 2012; 16 (1) 140
    CrossrefPubMedGoogle Scholar
  • 71 Yonemura K, Ohtake T, Matsushima H, Fujigaki Y, Hishida A. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease. Clin Nephrol 2004; 62 (3) 202-207
    CrossrefPubMedGoogle Scholar
  • 72 Playford EG, Bansal AS, Looke DF, Whitby M, Hogan PG. Hypercalcaemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J Infect 2001; 42 (2) 157-158
    CrossrefPubMedGoogle Scholar
  • 73 Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000; 6 (5) 442-447
    CrossrefPubMedGoogle Scholar
  • 74 Baughman RP, Janovcik J, Ray Et Al M. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (2) 113-120
    PubMedGoogle Scholar
  • 75 Mahévas M, Lescure FX, Boffa JJ , et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 2009; 88 (2) 98-106
    CrossrefPubMedGoogle Scholar
  • 76 Bullmann C, Faust M, Hoffmann A , et al. Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol 2000; 142 (4) 365-372
    CrossrefPubMedGoogle Scholar
  • 77 O'Brien GM, Baughman RP, Broderick JP, Arnold L, Lower EE. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis 1994; 11 (1) 34-36
    PubMedGoogle Scholar
  • 78 Tabuena RP, Nagai S, Handa T , et al. Diabetes insipidus from neurosarcoidosis: long-term follow-up for more than eight years. Intern Med 2004; 43 (10) 960-966
    CrossrefPubMedGoogle Scholar
  • 79 Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest 2002; 25 (7) 650-662
    CrossrefPubMedGoogle Scholar
  • 80 Miyoshi T, Otsuka F, Takeda M , et al. An elderly patient with sarcoidosis manifesting panhypopituitarism with central diabetes insipidus. Endocr J 2007; 54 (3) 425-430
    CrossrefPubMedGoogle Scholar
  • 81 Molina A, Mañá J, Villabona C, Fernández-Castañer M, Soler J. Hypothalamic-pituitary sarcoidosis with hypopituitarism. Long-term remission with methylprednisolone pulse therapy. Pituitary 2002; 5 (1) 33-36
    CrossrefPubMedGoogle Scholar
  • 82 Kimball MM, Wind JJ, Codispoti KE, Jones RV, Leiphart JW. Neurosarcoidosis presenting as an isolated intrasellar mass: case report and review of the literature. Clin Neuropathol 2010; 29 (3) 156-162
    CrossrefPubMedGoogle Scholar
  • 83 Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115 (4) 1158-1165
    CrossrefPubMedGoogle Scholar
  • 84 Miller MA, Bass HE. Effect of Acthar-c (ACTH) in sarcoidosis. Ann Intern Med 1952; 37 (4) 776-784
    CrossrefPubMedGoogle Scholar
  • 85 Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 2013; 19 (2) 130-136
    CrossrefPubMedGoogle Scholar
  • 86 Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17 (1) 60-66
    PubMedGoogle Scholar
  • 87 Matsumoto K, Yamasaki H, Akazawa S , et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996; 81 (7) 2621-2626
    PubMedGoogle Scholar
  • 88 Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 2012; 51 (6) 1112-1119
    CrossrefPubMedGoogle Scholar
  • 89 Friedman DS, Holbrook JT, Ansari H , et al; MUST Research Group. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 2013; 120 (8) 1571-1579
    CrossrefPubMedGoogle Scholar
  • 90 Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol 1993; 9 (1) 35-45
    CrossrefPubMedGoogle Scholar
  • 91 Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 2009; 15 (4) 155-160
    CrossrefPubMedGoogle Scholar
  • 92 Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 1988; 5 (2) 93-98
    PubMedGoogle Scholar
  • 93 Grossman JM, Gordon R, Ranganath VK , et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62 (11) 1515-1526
    CrossrefPubMedGoogle Scholar
  • 94 Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2011; 13 (3) 265-272
    CrossrefPubMedGoogle Scholar
  • 95 Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 2010; 104 (4) 564-570
    CrossrefPubMedGoogle Scholar
  • 96 Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J 1998; 11 (5) 1015-1020
    CrossrefPubMedGoogle Scholar
  • 97 Insogna KL, Dreyer BE, Mitnick M, Ellison AF, Broadus AE. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. J Clin Endocrinol Metab 1988; 66 (1) 72-75
    CrossrefPubMedGoogle Scholar
  • 98 Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8 (5) 470-476
    CrossrefPubMedGoogle Scholar
  • 99 Vorselaars AD, Wuyts WA, Vorselaars VM , et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013; 144 (3) 805-812
    CrossrefPubMedGoogle Scholar
  • 100 Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24 (3) 451-454
    CrossrefPubMedGoogle Scholar
  • 101 Ortiz-Alvarez O, Morishita K, Avery G , et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31 (12) 2501-2506
    PubMedGoogle Scholar
  • 102 Kremer JM, Alarcón GS, Lightfoot Jr RW , et al; American College of Rheumatology. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37 (3) 316-328
    CrossrefPubMedGoogle Scholar
  • 103 Visser K, Katchamart W, Loza E , et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68 (7) 1086-1093
    CrossrefPubMedGoogle Scholar
  • 104 Katchamart W, Bourré-Tessier J, Donka T , et al; Canadian 3e Initiative Consensus Group. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 2010; 37 (7) 1422-1430
    CrossrefPubMedGoogle Scholar
  • 105 Cremers JP, Drent M, Bast A , et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19 (5) 545-561
    CrossrefPubMedGoogle Scholar
  • 106 Baughman RP, Meyer KC, Nathanson I , et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 142 (5) e1S-e111S
    CrossrefPubMedGoogle Scholar
  • 107 Emery P, Breedveld FC, Lemmel EM , et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (6) 655-665
    CrossrefPubMedGoogle Scholar
  • 108 Kremer JM, Genovese MC, Cannon GW , et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137 (9) 726-733
    CrossrefPubMedGoogle Scholar
  • 109 Bremer JP, Ullrich S, Laudien M, Gross WL, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 2010; 28 (1) (Suppl. 57) 67-71
    PubMedGoogle Scholar
  • 110 Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32 (12) 1123-1134
    CrossrefPubMedGoogle Scholar
  • 111 Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007; 34 (9) 1934-1937
    PubMedGoogle Scholar
  • 112 Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36 (3) 162-169
    CrossrefPubMedGoogle Scholar
  • 113 Richards BL, Spies J, McGill N , et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007; 37 (2) 101-107
    CrossrefPubMedGoogle Scholar
  • 114 Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14 (2) 179-181
    CrossrefPubMedGoogle Scholar
  • 115 Wong SP, Chu CM, Kan CH, Tsui HS, Ng WL. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol 2009; 15 (8) 389-392
    CrossrefPubMedGoogle Scholar
  • 116 Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14 (5) 1117-1122
    CrossrefPubMedGoogle Scholar
  • 117 Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (2) 121-130
    PubMedGoogle Scholar
  • 118 Ansari A, Arenas M, Greenfield SM , et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28 (8) 973-983
    CrossrefPubMedGoogle Scholar
  • 119 Escousse A, Mousson C, Santona L , et al. Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: a family study. Transplant Proc 1995; 27 (2) 1739-1742
    PubMedGoogle Scholar
  • 120 Hagaman JT, Kinder BW, Eckman MH. Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010; 188 (2) 125-132
    CrossrefPubMedGoogle Scholar
  • 121 Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration 2013; 86 (5) 376-383
    PubMedGoogle Scholar
  • 122 Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17 (3) 185-190
    CrossrefPubMedGoogle Scholar
  • 123 Remuzzi G, Cravedi P, Costantini M , et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18 (6) 1973-1985
    CrossrefPubMedGoogle Scholar
  • 124 Hilderson I, Van Laecke S, Wauters A, Donck J. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant 2013;
    PubMedGoogle Scholar
  • 125 Zaidi AA, Devita MV, Michelis MF, Rosenstock JL. Mycophenolate mofetil as a steroid-sparing agent in sarcoid-associated renal disease. Clin Nephrol 2013;
    PubMedGoogle Scholar
  • 126 Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18 (1) 70-74
    PubMedGoogle Scholar
  • 127 Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59 (10) 1660-1661
    CrossrefPubMedGoogle Scholar
  • 128 Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135 (1) 27-31
    CrossrefPubMedGoogle Scholar
  • 129 Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100 (11) 2053-2059
    CrossrefPubMedGoogle Scholar
  • 130 Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53 (5) 788-791
    CrossrefPubMedGoogle Scholar
  • 131 Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127 (3) 1064-1071
    CrossrefPubMedGoogle Scholar
  • 132 Baughman RP, Drent M, Kavuru M , et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7) 795-802
    CrossrefPubMedGoogle Scholar
  • 133 Rossman MD, Newman LS, Baughman RP , et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (3) 201-208
    PubMedGoogle Scholar
  • 134 Judson MA, Baughman RP, Costabel U , et al; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (6) 1189-1196
    CrossrefPubMedGoogle Scholar
  • 135 Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135 (2) 468-476
    CrossrefPubMedGoogle Scholar
  • 136 Russell E, Luk F, Manocha S, Ho T, O'Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013; 43 (1) 119-124
    CrossrefPubMedGoogle Scholar
  • 137 Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Rev Port Pneumol 2007; 13: S47-S50
    PubMedGoogle Scholar
  • 138 Baughman RP, Shipley R, Desai S , et al; Sarcoidosis Investigators. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009; 136 (2) 526-535
    CrossrefPubMedGoogle Scholar
  • 139 Vorselaars AD, Verwoerd A, Van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43 (2) 602-609
    CrossrefPubMedGoogle Scholar
  • 140 Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25 (2) 143-149
    PubMedGoogle Scholar
  • 141 Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med 2014; 108 (1) 189-194
    CrossrefPubMedGoogle Scholar
  • 142 Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R ; T48 Investigators. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (1) 49-56
    PubMedGoogle Scholar
  • 143 Milman N, Andersen CB, Baslund B, Loft A, Iversen M. Does tumour necrosis factor-alpha inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas?. Clin Respir J 2007; 1 (2) 106-113
    CrossrefPubMedGoogle Scholar
  • 144 Baert F, De Vos M, Louis E, Vermeire S ; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem?. Acta Gastroenterol Belg 2007; 70 (2) 163-170
    PubMedGoogle Scholar
  • 145 Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006; 8 (4) R131
    CrossrefPubMedGoogle Scholar
  • 146 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5 (2) 119-133
    CrossrefPubMedGoogle Scholar
  • 147 Keane J, Gershon S, Wise RP , et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 148 Dixon WG, Hyrich KL, Watson KD , et al; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69 (3) 522-528
    CrossrefPubMedGoogle Scholar
  • 149 Takeuchi T, Tatsuki Y, Nogami Y , et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67 (2) 189-194
    CrossrefPubMedGoogle Scholar
  • 150 Gómez-Reino JJ, Carmona L, Angel Descalzo M ; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57 (5) 756-761
    CrossrefPubMedGoogle Scholar
  • 151 Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67 (1) 84-90
    CrossrefPubMedGoogle Scholar
  • 152 Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012; 31 (4) 631-636
    CrossrefPubMedGoogle Scholar
  • 153 Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007; 26 (11) 1969-1971
    CrossrefPubMedGoogle Scholar
  • 154 Daïen CI, Monnier A, Claudepierre P , et al; Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48 (8) 883-886
    CrossrefPubMedGoogle Scholar
  • 155 Mössner R, Thaci D, Mohr J , et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res 2008; 300 (3) 101-105
    CrossrefPubMedGoogle Scholar
  • 156 Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14 (4) 522-528
    CrossrefPubMedGoogle Scholar
  • 157 Sandborn WJ, Rutgeerts P, Enns R , et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146 (12) 829-838
    CrossrefPubMedGoogle Scholar
  • 158 Weinblatt ME, Keystone EC, Furst DE , et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48 (1) 35-45
    CrossrefPubMedGoogle Scholar
  • 159 Sandborn WJ, Hanauer SB, Rutgeerts P , et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56 (9) 1232-1239
    CrossrefPubMedGoogle Scholar
  • 160 Lahmer T, Knopf A, Lanzl I , et al. Using TNF-alpha antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2011; 50 (11) 2029-2034
    PubMedGoogle Scholar
  • 161 Kamphuis LS, Lam-Tse WK, Dik WA , et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184 (10) 1214-1216
    CrossrefPubMedGoogle Scholar
  • 162 Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012; 6 (4) 238-247
    CrossrefPubMedGoogle Scholar
  • 163 Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68 (5) 765-773
    CrossrefPubMedGoogle Scholar
  • 164 Sweiss NJ, Noth I, Mirsaedi M , et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (1) 46-54
    PubMedGoogle Scholar
  • 165 Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010; 30 (4) 339-353
    CrossrefPubMedGoogle Scholar
  • 166 Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71 (8) 1303-1308
    CrossrefPubMedGoogle Scholar
  • 167 Ramos-Casals M, Brito-Zerón P, Muñoz S , et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86 (4) 242-251
    CrossrefPubMedGoogle Scholar
  • 168 Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30 (8) 1864-1867
    PubMedGoogle Scholar
  • 169 Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128 (2) 1062-47
    CrossrefPubMedGoogle Scholar
  • 170 Utz JP, Limper AH, Kalra S , et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124 (1) 177-185
    CrossrefPubMedGoogle Scholar
  • 171 Dragnev D, Barr D, Kulshrestha M, Shanmugalisngam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep 2013; 2013: xx
    PubMedGoogle Scholar
  • 172 Sandborn WJ, Hanauer SB, Katz S , et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121 (5) 1088-1094
    CrossrefPubMedGoogle Scholar
  • 173 British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. Tubercle 1967; 48 (4) 257-272
    CrossrefPubMedGoogle Scholar
  • 174 Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23 (3 Pt 1) 487-489
    CrossrefPubMedGoogle Scholar
  • 175 Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425: 302-308
    PubMedGoogle Scholar
  • 176 Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160 (1) 192-197
    CrossrefPubMedGoogle Scholar
  • 177 O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986; 315 (12) 727-730
    CrossrefPubMedGoogle Scholar
  • 178 Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989; 111 (5) 437-438
    CrossrefPubMedGoogle Scholar
  • 179 Jover JA, Leon L, Pato E , et al. Long-term use of antimalarial drugs in rheumatic diseases. Clin Exp Rheumatol 2012; 30 (3) 380-387
    PubMedGoogle Scholar
  • 180 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69 (1) 20-28
    CrossrefPubMedGoogle Scholar
  • 181 Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62 (6) 775-784
    CrossrefPubMedGoogle Scholar
  • 182 Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12 (4) 294-304
    PubMedGoogle Scholar
  • 183 Araiza-Casillas R, Cárdenas F, Morales Y, Cardiel MH. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13 (2) 119-124
    CrossrefPubMedGoogle Scholar
  • 184 Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159 (2) 508-511
    CrossrefPubMedGoogle Scholar
  • 185 Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003; 124 (4) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 186 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155 (5) 1665-1669
    CrossrefPubMedGoogle Scholar
  • 187 Park MK, Fontana Jr JR, Babaali H , et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (2) 121-131
    PubMedGoogle Scholar
  • 188 Gottlieb AB, Matheson RT, Menter A , et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013; 12 (8) 888-897
    PubMedGoogle Scholar
  • 189 Schett G, Wollenhaupt J, Papp K , et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64 (10) 3156-3167
    CrossrefPubMedGoogle Scholar
  • 190 Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148 (2) 262-264
    CrossrefPubMedGoogle Scholar
  • 191 McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 2009; 146 (3) 233-246
    CrossrefPubMedGoogle Scholar
  • 192 Lee NS, Barber L, Akula SM, Sigounas G, Kataria YP, Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol 2011; 18 (8) 1306-1316
    CrossrefPubMedGoogle Scholar
  • 193 Gottenberg JE, Guillevin L, Lambotte O , et al; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64 (6) 913-920
    CrossrefPubMedGoogle Scholar
  • 194 Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75 (6) 568-570
    CrossrefPubMedGoogle Scholar
  • 195 Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618
    PubMedGoogle Scholar
  • 196 Aksoy S, Dizdar O, Hayran M, Harputluoğlu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009; 50 (3) 357-365
    CrossrefPubMedGoogle Scholar
  • 197 Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39 (5) 327-346
    CrossrefPubMedGoogle Scholar
  • 198 Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med 2011; 9: 36
    CrossrefPubMedGoogle Scholar
  • 199 Nardi A, Brillet PY, Letoumelin P , et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38 (6) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 200 Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Transl Res 2012; 160 (5) 321-331
    CrossrefPubMedGoogle Scholar
  • 201 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (3) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 202 Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med 2013; 107 (12) 2009-2013
    CrossrefPubMedGoogle Scholar
  • 203 Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol 2011; 49 (2) 198-201
    CrossrefPubMedGoogle Scholar
  • 204 Swigris JJ, Olson AL, Huie TJ , et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140 (5) 1261-1266
    CrossrefPubMedGoogle Scholar
  • 205 Crawshaw AP, Wotton CJ, Yeates DG, Goldacre MJ, Ho LP. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66 (5) 447-448
    CrossrefPubMedGoogle Scholar
  • 206 Vorselaars AD, Snijder RJ, Grutters JC. Increased number of pulmonary embolisms in sarcoidosis patients. Chest 2012; 141 (3) 826-827 , author reply 827
    CrossrefPubMedGoogle Scholar
  • 207 Robinson LR, Brownsberger R, Raghu G. Respiratory failure and hypoventilation secondary to neurosarcoidosis. Am J Respir Crit Care Med 1998; 157 (4 Pt 1) 1316-1318
    CrossrefPubMedGoogle Scholar
  • 208 Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130 (5) 1496-1502
    CrossrefPubMedGoogle Scholar